Search company, investor...
PolyPid company logo

PolyPid

polypid.com

Founded Year

2008

Stage

IPO | IPO

Total Raised

$96.7M

Date of IPO

6/26/2020

Market Cap

0.02B

Stock Price

0.84

About PolyPid

PolyPid is a global clinical-stage biopharmaceutical company focused on developing, manufacturing, and commercializing novel, locally administered therapies to improve surgical outcomes. The company's PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications. Its product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation, and cancer.

Headquarters Location

18 Hasivim St.

Petach Tikva, 4959376,

Israel

+972-74-719-5700

PolyPid's Product Videos

Compete with PolyPid?

Ensure that your company and products are accurately represented on our platform.

PolyPid's Products & Differentiators

    D-PLEX100

    sustained release antibiotics for post-surgical site infection reduction

Research containing PolyPid

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned PolyPid in 1 CB Insights research brief, most recently on Mar 24, 2020.

Expert Collections containing PolyPid

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PolyPid is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,565 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health IT

7,901 items

PolyPid Patents

PolyPid has filed 1 patent.

The 3 most popular patent topics include:

  • Colloidal chemistry
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/13/2020

10/18/2022

Surgery, Digestive system surgery, Implants (medicine), Surgical removal procedures, Surgical procedures and techniques

Grant

Application Date

2/13/2020

Grant Date

10/18/2022

Title

Related Topics

Surgery, Digestive system surgery, Implants (medicine), Surgical removal procedures, Surgical procedures and techniques

Status

Grant

Latest PolyPid News

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

Nov 29, 2022

The abstract will be available on  www.polypid.com  once the conference concludes. About PolyPid PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn . Contacts:

PolyPid Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PolyPid Rank

PolyPid Frequently Asked Questions (FAQ)

  • When was PolyPid founded?

    PolyPid was founded in 2008.

  • Where is PolyPid's headquarters?

    PolyPid's headquarters is located at 18 Hasivim St., Petach Tikva.

  • What is PolyPid's latest funding round?

    PolyPid's latest funding round is IPO.

  • How much did PolyPid raise?

    PolyPid raised a total of $96.7M.

  • Who are the investors of PolyPid?

    Investors of PolyPid include Aurum Ventures, Shavit Capital Fund, Chaim Hurvitz and Xenia Venture Capital.

  • Who are PolyPid's competitors?

    Competitors of PolyPid include Chiasma, Brainsgate, Nanocan Therapeutics, Erydel, Sol-Gel and 15 more.

  • What products does PolyPid offer?

    PolyPid's products include D-PLEX100.

Compare PolyPid to Competitors

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

E
Eratech srl

Eratech is a drug development company specialized in the field of inhalation drug delivery via nasal and pulmonary administration, for local and systemic therapies. Eratech offers to its clients the following selection of product development support services: Pharmacological-Toxicological, Pharmaceutical Development, Clinical Trials, Regulatory Affairs. nnn

S
Selective Amplifier Genes

Selective Amplifier Genes offers artificial genes that improve the functions of vectors for use in blood disorders

C
Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.

G
Glycologic

Glycologic Limited is a company dedicated to the creation of nutritional, clinical nutrition and drug delivery systems based on carbohydrates which overcome the limitations of other technologies. The Company utilises the properties of carbohydrates to develop customised solutions to a wide variety of nutritional and pharmaceutical problems.

G
Gel Med Sciences

GelMed Sciences, Inc. is commercializing three new agriculture product inventions initially developed by the Penn State University Research Foundation (PSRF). The company's offerings include a Poultry Feed Withdrawal Supplement (PFWS), a Livestock Genetic Marker, and a Gel Drug Delivery Systems which all aim to improve quality and/or output of agricultural products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.